Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

GSK - GSK plc So'nggi Yangiliklar | Finranks

Home

GSK

G

GSK plc (GSK)

NYQ – Real vaqt narxi. Valyuta: USD

53.84

-0.10 (-0.19%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

53.74

-0.10 (-0.19%)

Bozordan keyin: Mar 27, 2026, 6:55 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript

GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript

GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript

Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud

Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud

Shore Capital has reiterated its buy recommendation on GSK PLC (LSE:GSK, NYSE:GSK) with a fair value of 2,500p, arguing the pharmaceutical group's shares are too cheap given the scale of its growth ambitions and that two of the market's main concerns about the business are beginning to fade. The broker's analyst, Dr Sean Conroy, said GSK, which has a market capitalisation of around £79 billion, trades at 14 times his 2026 earnings estimate and 12 times his 2027 forecast, a level he described as undemanding relative to peers on comparable growth.

GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer

GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer

GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.

Dividend Income: Lanny's January 2026 Summary

Dividend Income: Lanny's January 2026 Summary

Dividend income is the fruit from the labor of investing your money in the stock market. The power of compounding and dividend reinvestment is a wonderful component of the portfolio. In total, dividend increases created $57.57 in additional passive dividend income.

Here's Why GSK (GSK) is a Strong Value Stock

Here's Why GSK (GSK) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

US FDA approves GSK's drug for liver disease related itching

US FDA approves GSK's drug for liver disease related itching

The U.S. Food and ‌Drug Administration approved GSK's drug for severe ⁠relentless itching caused by a type of liver disease, the company said on Thursday, making ‌it ⁠the first treatment greenlit for the ⁠condition.

TrumpRx lists many medicines at prices higher than paid in UK

TrumpRx lists many medicines at prices higher than paid in UK

U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.

Videolar

3 International Stocks to Buy for 2026

BREAKING: Trump strikes major deal with UK on drug pricing

Press-relizlar

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

PHILADELPHIA--(BUSINESS WIRE)--GSK's RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk.

04.11.2025

Neutral

3 Dividend Stocks for November 2025

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc (GSK), under which GSK will acquire all of the outstanding equity interests in 35Pharma. The acquisition includes HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.